VIR - Vir Biotechnology reports data from Hepatitis B program

Vir Biotechnology (NASDAQ:VIR) said preliminary day showed that a six-dose regimen of VIR-2218 provided greater and more durable reductions in hepatitis B surface antigen (HBsAg) than a two-dose regimen, in a phase 2 trial. The company presented data from its hepatitis B virus (HBV) trial program, including results from the ongoing phase 2 study of VIR-2218; from an ongoing phase 1 trial of VIR-3434; and preclinical data evaluating both investigational compounds as monotherapy and in combination, at the International Liver Congress (ILC) 2022. A phase 1 trial evaluating VIR-3434 showed that a single dose (6 mg, 18 mg, 75 mg or 300 mg) resulted in a rapid reduction of hepatitis B surface antigen, with the largest and most durable response with the 300 mg dose. In addition, the company said that preclinical in vivo data showed that the combination of both investigational compounds resulted in greater HBsAg reductions than either compound alone.

For further details see:

Vir Biotechnology reports data from Hepatitis B program